Abstract

Background: The Epstein-Barr virus (EBV) causes various B-cell lymphomas and epithelial malignancies, including gastric cancer (GC) at frequencies ranging from 5 to 10% in adenocarcinomas (ADK) to 80% in GC with lymphoid stroma (GCLS). Using high-sensitivity methods, we recently detected EBV traces in a large cohort of EBV-negative B-cell lymphomas, suggesting a hit-and-run mechanism.

Methods: Here, we used routine and higher-sensitivity methods [droplet digital PCR (ddPCR) for EBV segments on microdissected tumour cells and RNAscope for EBNA1 mRNA] to assess EBV infection in a cohort of 40 GCs (28 ADK and 12 GCLS).

Results: ddPCR documented the presence of EBV nucleic acids in rare tumour cells of several cases conventionally classified as EBV-negative (ADK, 8/26; GCLS, 6/7). Similarly, RNAscope confirmed EBNA1 expression in rare tumour cells (ADK, 4/26; GCLS, 3/7). Finally, since EBV induces epigenetic changes that are heritable and retained after complete loss of the virus from the host cell, we studied the methylation pattern of EBV-specifically methylated genes (Timp2, Eya1) as a mark of previous EBV infection. Cases with EBV traces showed a considerable level of methylation in Timp2 and Eya1 genes that was similar to that observed in EBER-ISH positive cases and greater than cases not featuring any EBV traces.

Conclusions: These findings suggest that: (a) EBV may contribute to gastric pathogenesis more widely than currently acknowledged and (b) indicate the methylation changes as a mechanistic framework for how EBV can act in a hit-and-run manner. Finally, we found that the viral state was of prognostic significance in univariate and multivariate analyses.

Keywords: Gastric adenocarcinoma, Gastric cancer with lymphoid stroma, Epstein Barr Virus, Hit and run mechanism

Introduction

The Epstein-Barr virus (EBV) is a gamma-herpes virus that infects more than 95% of healthy adults worldwide. While most people carry EBV as a life-long asymptomatic infection, in some people, the virus is associated with a number of B cell and epithelial cell malignancies, including Burkitt’s Lymphoma (BL), nasopharyngeal carcinoma (NPC) and gastric cancer (GC) [1, 2]. In order to establish a lifelong carrier state, the virus expresses a set of viral proteins as well as viral miRNAs that may impact key cellular pathways and host cell homeostasis [3–5]. EBV is also able to elude the immune response [6–8] and to manipulate the host epigenetic machinery, resulting in long-lasting host epigenetic reprogramming [9–11]. However, its possible contribution to the pathogenesis of EBV-associated diseases is largely unknown.
The role of EBV is further confounded by the less than total association of the virus with histologically and molecular similar tumours. Indeed, it has been proposed that the virus may be responsible also for tumours diagnosed as EBV negative by a mechanism of hit-and-run [12,13]. This theory suggested that EBV can mediate cellular transformation (hit) through its viral proteins and being progressively lost (run) from the host cell after inducing heritable changes in the cellular genes [14]. The loss of EBV genome occurs when there is no selective pressure for its maintenance, and it is mainly due to the known imperfect duplication and asymmetric partitioning of EBV episomes during S-phase and M-phase respectively [15,16]. In the meantime, the acquisition of somatic mutations in cellular oncogenes/tumor suppressor genes [17,18] will functionally compensate for the loss of EBV genome.

Support for this idea comes from anecdotal case report of NPC and BL primary tumours and cell lines which after several cell cycles spontaneously lost the viral episomal genome [19–22]. Furthermore, fragments of the EBV genome in single cells have been demonstrated in a series of Hodgkin and non-Hodgkin lymphomas and cell lines that by standard criteria (EBER in situ hybridization or EBNA1 immunohistochemistry) would be classified as virus-negative [12,23].

These findings prompted us to investigate the presence of EBV traces in other EBV-linked malignancies where the virus seems to play an important role in the development and progression of the tumour, such as GC.

The percentage of EBV infection associated with GC tumours is highly variable [24]. Gastric cancer with lymphoid stroma (GCLS), also known as medullary or lymphoepithelioma-like GC (LELC), is a subset of GC known to harbour the EBV genome in a range varying from 22.5 to 100% of cases, in respect to the ordinary-type adenocarcinomas (ADK) cases where the virus is detected in 5–10% of tumours [25]. In The Cancer Genome Atlas (TCGA) project, GC is classified according to its molecular biology into EBV-associated GC (EBVaGC), microsatellite instable tumours (MSI), genomically stable (GS), and chromosomally instable (CIN) [26]. Although the impact of EBV is still comprehensively unknown, several papers suggest that the virus contributes to GC tumorigenesis by inducing epigenetic changes [27,28].

In fact, EBV-positive tumours show a higher prevalence of DNA hypermethylation than the other GC subtypes. Matsusaka and colleagues, using Illumina’s Infinium Bead Array, identified three epigenotypes groups based on the EBV status and methylation degree: (1) genes specifically methylated in the EBVaGC (such as Temp2), (2) genes methylated both in EBV positive and EBV negative/high tumours (such as Eya1) and, (3) genes methylated in all gastric cancers [29,30]. Both TIMP2 and EYA1 proteins have been identified as tumour promoters in various cancers inducing cell migration and tumour metastasis [31,32]. In addition, all EBV-positive tumours display amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also named PD-L2) and carry a lower number of mutations in genes such as TP53, CDH1, RHOA, than the other GC subgroups where these genes are found to be highly mutated [26,33]. This pattern of mutations seems to mirror what has been observed in EBV-associated lymphomas such as BL and Hodgkin lymphoma (HL), where a hit-and-run mechanism has been proposed [23,34].

The aim of this work was to investigate the presence of EBV traces also in GCs conventionally classified as EBV-negative by applying highly sensitive methods for EBV detection such as droplet digital PCR (ddPCR) for conserved EBV genomic regions and RNAscope for EBNA1 mRNA in situ detection [15,35]. In addition, we studied the methylation pattern of genes specifically methylated by the virus (e.g., Temp2) as indirect proof of the hit-and-run mechanism. Finally, we investigated the impact of EBV presence (EBERs or EBV traces) on the overall survival (OS) of all patients.

Materials and methods

Cases selection

7 EBER-ISH positive GCs, selected as gold standard cases, were compared to 33 EBER-ISH negative consecutive GC observed at the Department of Surgical Oncology of Siena University Hospital in the year 2010 to allow a large prospective cohort study based on a significant long follow up. Histologic diagnosis was determined in accordance with the World Health Organization (WHO) criteria for gastric tumours. Among 7 EBER-ISH positive GCs, 5 were classified as GCLS and 2 as ADK. The remaining 33 EBER-ISH negative consecutive GC samples were grouped as 26 ADK and 7 GCLS (Fig. 1A–D). All the procedures were carried out automatically on representative paraffin sections from each case by Bench Mark Ultra (Ventana, Monza, Italy). The clinicopathologic features of cases consisting of age, gender and site were reported in Table 1.

EBER-in situ hybridization

To validate the presence of EBV, EBER-ISH staining was performed on all 5 μm FFPE cases by an automated staining system (Ventana BenchMark ULTRA, Roche diagnostic, Monza-Italy), as previously described [18]. All steps were performed inside the instrument, from deparaffinization to counterstaining with appropriate positive and negative controls included in each staining run. A control slide prepared from a paraffin-embedded tissue
block containing EBV-positive metastatic nasopharyngeal carcinoma in a lymph node accompanied each hybridization run. The EBER-ISH stained sections were scanned and analysed by Hamamatsu NanoZoomer-XR digital whole slide scanner.

**Laser capture microdissection (LCM)**
The neoplastic cells of each GC sample (including those positive at EBER-ISH assay) were microdissected from EBER-ISH stained 3 μM-thick FFPE sections using a PixCell II laser capture microdissector (Arcturus Engineering, MGW, Florence, Italy). Multiple areas, each one containing ~40–50 cells, were harvested to collect a total number of ~200,000 cells. The EBER-ISH staining allowed us, in cases with EBER-negative cells, to exclude by microdissection even a small single EBER-positive reactive lymphocyte that might impact the following ddPCR analyses.

**DNA extraction and processing before droplet digital PCR**
DNA was extracted from FFPE of the original neoplastic samples using NucleoSpin Tissue (Macherey-Nagel, Italy) following manufacturer’s instructions. Positive and negative controls in addition to a blank control (H₂O) were included in all runs. The amount and quality of DNA were evaluated by measuring the optic density (OD) at 260 nm, the 260/230 and the 260/280 ratios using a Nanodrop spectrophotometer (ND-100, Nanodrop, Thermo Scientific, Celbio, Italy).

**Droplet digital PCR assay to measure the absolute copy number of EBV genome load**
ddPCR was performed using 200 ng of DNA, 1 × ddPCR Supermix for Probes (BioRad, Hercules, CA, USA), 900 nM of each primer, and 250 nM of the probe in a total volume of 22 μL, as previously described [23]. Among the fragments of the EBV genome, we choose to target in our cases BamHI-W and EBNA1, the most conserved region of EBV genome [36, 37]. BamHI-W is a reiterated sequence present at approximately ten copies per EBV genome and appears to be the most sensitive method to prove the presence of the viral genome, whereas EBNA1 probe targets a single-copy highly conserved gene, essential for maintaining the virus long-term in dividing cells. The absolute copy number of each viral assays was calculated by Bio-Rad software and showed as number of copies/μl. As previously reported, we used as biological negative controls a sample of Hair Cell Leukemia (HCL), whom has never been associated with EBV. In addition, we used water as technical negative controls for the ddPCR amplification (data not shown) [23].

**In situ detection of EBNA1 mRNA by RNAscope assay**
RNAscope is an amplified ISH assay more sensitive than standard ISH for EBV-encoded RNAs to detect viral gene expression. It employs a multiple probe pair design strategy in which two independent probes within each pair (double Z probes) have to hybridize to the target sequence in tandem next to each other for signal.
amplification to occur, which improves the signal-to-noise ratio. Signal amplification is achieved by a cascade of hybridization of a nucleic acid pre-amplifier followed by multiple amplifiers that serve as a substrate for the subsequent binding of chromogenic molecules to the numerous binding sites in each amplifier. RNAscope is made to work for optimal RNA detection. The RNAscope workflow does not have any DNA-specific denaturing steps that will hinder RNA probe binding.

RNA in situ hybridization was performed using the RNAscope 2.0 HD Red Chromogenic Reagent Kit (Advanced Cell Diagnostic, CA), V-EBV-EBNA1 and V-EBV-EBER1 target probe, according to the manufacturer’s instructions. Each sample was quality-controlled

| Case Number | Age | Gender | Site | Histological Type |
|-------------|-----|--------|------|-------------------|
| #1          | 78  | M      | Lesser curvature | ADK   |
| #2          | 52  | M      | Lesser curvature |       |
| #3          | 80  | M      | Lesser curvature |       |
| #4          | 84  | M      | Lesser curvature |       |
| #5          | 77  | M      | Pylorus          |       |
| #6          | 81  | M      | Pylorus          |       |
| #7          | 74  | M      | Cardia           |       |
| #8          | 58  | M      | Antrum, pylorus  |       |
| #9          | 84  | M      | Lesser curvature |       |
| #10         | 70  | F      | Antrum           |       |
| #11         | 73  | F      | Antrum           |       |
| #12         | 63  | M      | Antrum, pylorus  |       |
| #13         | 63  | M      | Body of stomach, fundus |   |
| #14         | 50  | M      | Cardia           |       |
| #15         | 90  | F      | Body of stomach, antrum |   |
| #16         | 76  | M      | Antrum           |       |
| #17         | 80  | M      | Lesser curvature |       |
| #18         | 79  | M      | Body of stomach, antrum |   |
| #19         | 80  | F      | Lesser curvature |       |
| #20         | 71  | F      | Greater curvature |       |
| #21         | 89  | F      | Lesser curvature |       |
| #22         | 89  | F      | Pylorus, antrum,body of stomach |   |
| #23         | 85  | M      | Angulus, lesser curvature |   |
| #24         | 63  | M      | Lesser curvature |       |
| #25         | 69  | M      | Cardia, antrum   |       |
| #26         | 70  | M      | Antrum           |       |
| #27         | 64  | M      | Antrum           |       |
| #28         | 61  | M      | Antrum           |       |
| #29         | 59  | F      | Angulus          | GCLS  |
| #30         | 75  | F      | Antrum, lesser curvature |   |
| #31         | 78  | F      | Antrum           |       |
| #32         | 61  | F      | Body of stomach  |       |
| #33         | 92  | M      | Lesser curvature |       |
| #34         | 82  | M      | Cardia           |       |
| #35         | 76  | F      | Antrum           |       |
| #36         | 72  | M      | Cardia, body of stomach, Antrum |   |
| #37         | 83  | M      | Fundus           |       |
| #38         | 78  | F      | Cardia           |       |
| #39         | 46  | M      | Body of stomach, lesser Curvature |   |
| #40         | 69  | F      | Body of stomach, antrum |   |
for RNA integrity with a probe specific to the housekeeping PPIB mRNA used as positive control. Signal detection was performed by hybridizing the FastRed probe mix (RED-A and RED-B) on each sample and counterstaining the section with haematoxylin. RNA staining signals were identified as red punctate dots also visible by optical microscope. RNAscope scores were obtained independently by two pathologists (SL, LL) by counting the red dots per cell in ten high magnification field (40X).

Background staining was evaluated using a negative control probe specific for bacterial dihydrodipicolinate reductase (dapB); all gastric cancer cases analysed did not show any dots for dapB in any cells (data not shown) [35]. RNase (Qiagen, Hilden, Germany) pre-treatment, at 5 mg/mL final concentration in 1X PBS, was performed to demonstrate lack of signal after RNAscope protease digestion step.

**RNAscope and immunofluorescence (IF) staining for the simultaneous detection of EBNA1 mRNA detection and pan-keratin marker**

Since EBNA1 mRNA signals detected by RNAscope can be visualized by an epifluorescence microscope, to further confirm the presence of EBNA1 mRNA in neoplastic cells, we performed a PanKeratin immunofluorescence on the same EBNA1 mRNA RNAscope stained section. Briefly, after deparaffinization and rehydration, heat-induced antigen retrieval was performed using a citrate-based solution (pH 6.0). We investigated the presence of Pan-Keratin using the AE1/AE3/PCK26 antibody (Ventana, 760–2595, Tucson, USA) and the fluorophore-conjugated secondary antibody FITC (MerkMillipore, AP124F, Darmstadt, Germany). The colour assignment and staining location is green-membranous. In order to detect nuclei signals, 40,6-diamidino-2-phenylindole (DAPI, ProLong™ Diamond Antifade Mountant with DAPI, P36966, Invitrogen, Country) was added to the slides. Tissue sections from the same set of cases and without antibody/fluorophore were used as negative control. The acquisition of multiplex IF staining reaction were performed using Tissue FAXSFluo slide scanning system (TissueGnostics, Vienna, Austria) based on a Zeiss Axio Imager Z2 upright epifluorescence microscope.

**Methylation studies**

Genomic DNA was extracted from five 5-μm-thick whole sections of FFPE gastric cancer sections using the NucleoSpin Tissue extraction kit (Macherey–Nagel, Germany) according to the manufacturer’s instructions. The amount and quality of DNA were evaluated by measuring the optical density (OD) at 260 nm, the 260/230 and the 260/280 ratios using a Nanodrop spectrophotometer (NanoDrop Technologies LIT, USA). 300 ng of DNA from each sample were used for bisulfite conversion, as previously described [23]. Unmethylated cytosine was converted to uracil with the EpiTect Fast DNA bisulfite kit (Qiagen, Hilden, Germany, 59,824) according to the manufacturer’s instructions. Human HCT116 DKO Non-methylated and Methylated DNA (Zymo Research, USA, D5014-1/2) were used as standard controls. The signal and target CpGs were evaluated by using the PyroMark Q96 ID System (Qiagen, Hilden, Germany) which converts the pyrograms to numerical values for peak heights and calculates the proportion of methylation at each base as a C/T ratio. Along with standards, a cytosine not followed by a guanine, which was not methylated, served as an internal control to verify the efficiency of bisulfite conversion.

**Statistical analysis**

Kaplan–Meier curves for the three viral states were drawn and statistically compared pairwise by means of the log rank test. The individual prognostic power (univariate analysis) of the various clinicopathological factors, in relation to survival time, was statistically assessed by Cox survival regression. The identification of a multivariate model explaining survival by combinations of statistically significant prognostic factors was also investigated, while still using Cox survival analysis. For all statistical analyses, the significance level was set at 95% (p ≤ 0.05).

**Results**

**Findings at in situ hybridization (ISH)**

The presence of EBV was detected in 2/28 (7%) ADK and in 5/12 (42%) GCLS samples (Fig. 1C–F) whereas the remaining cases were negative (Fig. 1B–E). The EBER-ISH positive case showed a distinctive diffuse nuclear stain. The intensity varied slightly from tumour to tumour but was consistent within the same tumour. No relationship was found between the intensity of EBER-1 expression and any clinicopathological features.

**Viral genome load by droplet digital PCR in GC tumours**

The neoplastic cells of each GC sample (including those positive at EBER-ISH) were microdissected from EBER-ISH stained FFPE sections and screened by ddPCR to independently measure the absolute copy numbers of EBNA1 and BAMH1-W fragments. As expected, ddPCR analysis of the EBER-ISH positive cases (2 ADK and 5 GCLS) revealed high viral loads of EBNA1 (ADK, EBNA1: from 1287 to 1314, with an average of 1300; GCLS, EBNA1: from 587 to 5100, with an average of 1095; GCLS, BAMH1-W: from 587 to 5100, with an average of 1095; GCLS, BAMH1-W: from
to that observed in specimens classified as EBER-ISH positive cases (2ADK, 5 GCLS) was compared by ddPCR (ADK: from 6 to 8, with an average of 7; GCLS: cases classified as EBER-ISH negative but EBV positive). On the other hand, single red dots were only found in scattered populations isolated through microdissection from conventional EBV-negative biopsies. ddPCR represents a robust tool able to essentially detect a single DNA template sequestered into a droplet containing even only one copy of the template target DNA. This approach allowed us to overcome the higher quantification variability of BamHI-W as reported by Sanosyan et al. Traces of a previous EBV infection were also confirmed and visualized by RNAse for EBNA1 mRNA in 4/26 ADK and in 3/7 GCLS. Interestingly, the RNAse staining often consisted of a single dot per cell in contrast to the more abundant EBNA1 labelling of infected EBER-positive GC cells that can be occasionally observed in tissue biopsies. Furthermore, by combing the RNAse staining and IF detecting pan-keratin marker, we confirmed the

**mRNA detection assays for the detection of EBNA1 mRNA in pan-keratin positive cells**

To identify the morphological nature of cells contributing to the positive signals in ddPCR, we performed an in situ EBNA1 and EBER1 detection by applying RNAse assay. The RNAse assay for EBNA1 consistently documented the presence of multiple red dots in the nuclei of neoplastic cells of all EBER-ISH positive GC cases (ADK: from 2500 to 2600, with an average of 2550; GCLS: from 2900 to 3000, with an average of 2950) (Table 2). On the other hand, single red dots were only found in scattered rare cells of 4/26 (15%) ADK and of 3/7 (43%) GCLS cases classified as EBER-ISH negative but EBV positive by ddPCR (ADK: from 6 to 8, with an average of 7; GCLS: from 8 to 12, with an average of 10) (Fig. 2A–C; Table 2). Otherwise, all EBER-ISH negative/ddPCR negative samples did not show any EBNA1 signals (data not shown) while showing positivity for the PPPI control gene (data not shown). Finally, our results with RNAse pre-treatment demonstrate a lack of signal after digestion (data not shown). To further confirm the neoplastic nature of EBNA1 positive cells, the EBNA1 mRNA positive sections were re-stained for pan-keratin immunofluorescent marker for the detection of GC tumour cells. A strong pan-keratin expression (green staining) was detected in the vast majority of cells of all GC cases while only scattered pan-keratin positive cells displayed a red punctate signal of EBNA1 mRNA (Fig. 2B, C, Inset).

Furthermore, our samples were tested with RNAse assay for EBER1. The EBER-ISH positive cases showed a strong staining (data not shown), while it was negative in the cases with only traces of EBNA1 and BamHI-W by ddPCR (data not shown). Conversely, all EBER-ISH negative/ddPCR negative samples did not show any EBER1 signals (data not shown).

**Methylation assay findings**

The methylation status of Eya1 and Timp2 genes in 7 EBER-ISH positive cases (2ADK, 5 GCLS) was compared to that observed in specimens classified as EBER-ISH negative/ddPCR-positive cases or EBER-ISH negative/ddPCR-negative. Timp2 and Eya1 presented a quite similar methylation pattern in both EBER-ISH positive and EBER-ISH negative/ddPCR-positive groups (18 and 16.5% respectively for Timp2; 18.25% and 15.9% for Eya1) and the lowest level of methylation in the EBER-negative/ddPCR-negative group (6% Timp2; 6.8% Eya1) (Fig. 3). P values were calculated according to T-test.

**Survival analysis**

EBVaGCs are reported to be correlated with lower T and N stages, outlining a better prognosis than the EBER-ISH negative cases, especially during the early stage in the submucosa. However, these findings are contradicted by other papers which highlight no differences in survival between EBVaGC and EBV-negative gastric carcinoma (EBVnGC) cases after surgery and/or conventional chemotherapy. In our series, Kaplan–Meier curves showed that EBER-ISH positive cases have significantly better overall survival (OS) than EBER-ISH negative cases. Although not significant, a notable difference was also found in cases with EBV traces than EBER-ISH negative (Fig. 4). In our series, univariate Cox survival analysis showed that only viral state (including EBER-ISH negative, EBV traces and EBER-ISH positive) and T-stage were significantly correlated (p = 0.05) with OS (Tables 3, 4). However, multivariate analysis did not show significant prognostic independence between viral state and T-stage (p > 0.05) and no significant multivariate model could be identified.

**Discussion**

Through this study, we demonstrated the presence of EBV traces in EBER-ISH negative GC cases by applying highly sensitive methods for the viral genome detection, such as ddPCR and RNAse. In particular, ddPCR showed the presence of BamHI-W and/or EBN.

A1 segment regions in 8/26 ADK and in 6/7 GCLS cell populations isolated through microdissection from conventional EBV-negative biopsies. ddPCR represents a robust tool able to essentially detect a single DNA template sequestered into a droplet containing even only one copy of the template target DNA. This approach allowed us to overcome the higher quantification variability of BamHI-W as reported by Sanosyan et al. Traces of a previous EBV infection were also confirmed and visualized by RNAse for EBNA1 mRNA in 4/26 ADK and in 3/7 GCLS. Interestingly, the RNAse staining often consisted of a single dot per cell in contrast to the more abundant EBNA1 labelling of infected EBER-positive GC cells that can be occasionally observed in tissue biopsies. Furthermore, by combing the RNAse staining and IF detecting pan-keratin marker, we confirmed the
Table 2 Detection of EBV genome by applying conventional (EBER-ISH) and unconventional methods (ddPCR, RNAscope) in two different histological types of GC (ADK, GCLS)

| Case Number | Assay | Histological Type |
|-------------|-------|-------------------|
|             | EBER-ISH EBERs | ddPCR BamHI (copies/ul) | ddPCR EBNA1 (copies/ul) | RNAscope EBNA1 mRNAs (score) |
| #1          | −      | 2                 | 0                   | −                           | ADK               |
| #2          | −      | 0                 | 0                   | −                           |                   |
| #3          | +      | 988               | 1287                | 2500                       |
| #4          | −      | 0                 | 0                   | −                           |
| #5          | −      | 0                 | 0                   | −                           |
| #6          | −      | 0                 | 0                   | −                           |
| #7          | −      | 0                 | 0                   | −                           |
| #8          | −      | 0                 | 0                   | −                           |
| #9          | −      | 0                 | 0                   | −                           |
| #10         | −      | 0                 | 0                   | −                           |
| #11         | −      | 2.2               | 0                   | −                           |
| #12         | −      | 9.8               | 1.5                 | 8                           |
| #13         | −      | 0                 | 0                   | −                           |
| #14         | −      | 0                 | 0                   | −                           |
| #15         | −      | 1.4               | 0                   | 6                           |
| #16         | −      | 0.3               | 0                   | −                           |
| #17         | −      | 0.5               | 0                   | −                           |
| #18         | −      | 0                 | 0                   | −                           |
| #19         | −      | 0                 | 0                   | −                           |
| #20         | −      | 0                 | 0                   | −                           |
| #21         | −      | 1.5               | 0.9                 | 8                           |
| #22         | −      | 0                 | 0                   | −                           |
| #23         | −      | 0                 | 0                   | −                           |
| #24         | −      | 5.7               | 0                   | 7                           |
| #25         | −      | 0                 | 0                   | −                           |
| #26         | −      | 0                 | 0                   | −                           |
| #27         | −      | 0                 | 0                   | −                           |
| #28         | +      | 1202              | 1314                | 2600                        |
| #29         | −      | 0.52              | 0.17                | −                           | GCLS              |
| #30         | −      | 41.85             | 4                   | 10                          |
| #31         | −      | 19.1              | 2.03                | 8                           |
| #32         | −      | 3.23              | 0.53                | 12                          |
### Table 2 (continued)

| Case Number |          | Assay | EBER-ISH | ddPCR | EBERs | BamHi (copies/ul) | EBNA1 (copies/ul) | EBNA1 mRNAs (score) | Histological Type |
|-------------|----------|-------|----------|-------|-------|------------------|------------------|-------------------|------------------|
| #33         |          |       |          | 0.94  | 0.48  | –                | –                | –                 | –                |
| #34         |          |       |          | 0.46  | 0.18  | –                | –                | –                 | –                |
| #35         |          |       |          | 0      | 0     | –                | –                | –                 | –                |
| #36         |          |       | +        | 6460  | 2847  | 3000             |                  |                   | –                |
| #37         |          |       | +        | 1410  | 5100  | 2900             |                  |                   | –                |
| #38         |          |       | +        | 2710  | 1351  | np               |                  | np                | –                |
| #39         |          |       | +        | 466   | 152   | np               |                  | np                | –                |
| #40         |          |       | +        | 2089  | 587   | np               |                  | np                | –                |
| HCL         |          |       |          | 0     | 0     | –                | –                | –                 | –                |
| HCL         |          |       |          | 0     | 0     | –                | –                | –                 | –                |
| HCL         |          |       |          | 0     | 0     | –                | –                | –                 | –                |

**Fig. 2** Sensitive in situ detection of EBV by RNAscope assay and immunofluorescence: Single red dot, produced by EBNA1 mRNA probes, were detected in EBER-ISH negative cases (A–B: GCLS; C: ADK). Double staining pan-keratin (IF, green) and EBNA1 (RNAscope, red) showed the presence of EBV traces in GC neoplastic cells (inset). Original magnification: 40X.
Fig. 3  Methylation assay findings: The methylation level of Timp2 (B) and Eya1 (A) in 7 GC EBER-positive cases overlapped that detected in 14 GC EBER-negative/ddPCR-positive cases, whereas it was higher than observed in EBER-negative/ddPCR-negative cases. P values were calculated according to T-test.

Fig. 4  Kaplan–Meier curves of overall survival (OS) in the different patient groups. Kaplan–Meier curve showed a significantly better OS in EBER-ISH positive cases (C) than EBER-ISH negative cases (A). Although not significant, a notably difference was also found in cases with EBV traces (B) than EBER-ISH negative (A).
neoplastic nature of EBNA1 mRNA positive cells. These methodologies, directly assessing the presence of the virus in conventional EBV-negative primary tumours, suggest that EBV infection might have happened in the early pathogenesis of a significantly greater proportion of GC cases than commonly thought, in keeping with the hit-and-run hypothesis [15, 41]. This theory postulates that the transforming events initially provided by the virus are later functionally replaced by stable (epi)genetic changes of the host cell. Meanwhile, the acquisition of somatic mutations in cellular oncogenes/tumor suppressor genes will be functionally compensated for the loss of EBV genome. According to the hit and run hypothesis most of the EBV genome may be lost due to the imperfect duplication and asymmetric portioning of EBV episodes during S-phase and M-phase respectively. EBNA1 and BAMHI-W, which are the most conserved region of the viral genome, may be linearly integrated into the host genome and contribute to the traces detected by us, while other parts of EBV genome may be completely lost [36, 37, 42]. Indeed, our detection of EBNA1 and BAMHI-W, and not EBER, may be the result of such a phenomenon [43]. Numerous evidence suggests that the EBV genome can randomly integrate at vulnerable sites of the cellular genome resulting in host genome instability or deregulated gene expression [36, 44–46]. At the (epi)genetic level, EBVaGCs are quite different from EBVnGCs, presenting a gain-of-function in oncogenes and loss-of-function in tumour suppressor genes [18]. EBV infection has been described as a determinant factor of epigenetic alterations both in the viral and cellular genomes, suggesting a direct viral-mediated epigenetic modification with consequent EBVaGC tumourigenesis. The prevalence of DNA hypermethylation is reported to be significantly higher in EBVaGCs when compared to EBVnGCs. The EBV-induced epigenetic changes are heritable and not dependent on continued viral gene expression [14, 16, 34, 47]. Moreover, as they are retained after complete loss of the virus from the host cell as a mark of previous EBV infection, the methylation changes may provide a mechanistic framework for how the virus can act in a hit-and-run manner. Based on that, we studied the methylation status of genes reported to be extensively higher methylated in EBVaGCs than EBVnGCs such as Timp2 and Eya1 [29]. Our results showed that Timp2 exhibited in GC harbouring only traces of EBV infection, a considerable level of methylation similar to that observed in conventional EBER-ISH positive cases and greater than in cases not featuring any traces of EBV infection, thus confirming the tight association between EBV infection and Timp2 promoter methylation. A similar methylation pattern was also demonstrated for Eya1. Although the hit-and-run hypothesis is difficult to formally prove and our results are not a direct proof of it, altogether our findings are in accordance with the concept that EBV can be largely lost from the tumour cells and leaves epigenetic vestiges as proof of its previous infection. Finally, multivariate analysis displayed that viral state and T stage are non-independent prognostic factors, suggesting that the viral state may influence the tumour size, possibly by inducing a tumour microenvironment (TME) not favourable for the tumour growth [48, 49]. However, due to the small sample size reported in the present paper, further studies are needed to confirm our results in a larger cohort of cases.

### Conclusion

In conclusion, although based on a small sample size, our findings expand EBV contribution to gastric pathogenesis more widely than currently acknowledged and indicate the methylation changes as a mechanistic framework for how EBV can act in a hit-and-run manner. Finally, we found that the viral state was of prognostic significance in univariate and multivariate analyses, supporting the efforts toward the development of prophylactic vaccination strategies against this virus.
3. Ambrosio MR, Navari M, Di Lisio L, Leon EA, Onnis A, Gazaneo S, et al.
4. Cai X, Schäfer A, Lu S, Bille JP, Desrosiers RC, Edwards R, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2006;2(3): e23.
5. Piccaluga PP, Navari M, Di Falco G, Ambrosio MR, Lazzi S, Fuligni F, et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget. 2016;7(11):224–40.
6. Thorley-Lawson DA. EBV persistence-introducing the virus. Curr Top Microbiol Immunol. 2015;390(Pt 1):151–209.
7. Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res. 2014;58(2–3):268–76.
8. Granai M, Mundo L, Akara AU, Siciliano MC, Rizvi H, Mancini V, et al. Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program. Infect Agent Cancer. 2020;15:28.
9. Scott RS. Epstein-Barr virus: a master epigenetic manipulator. Curr Opin Virol. 2017;26:74–80.
10. Vargas-Ayala RC, Jay A, Manara F, Marouli MA, Hernandez-Vargas H, Diederichs A, et al. Interplay between the epigenetic enzyme lysine (K)-specific demethylase 2B and Epstein-Barr virus infection. J Virol. 2019. doi:10.1128/JVI.00273-19.
11. Leonard S, Wei W, Anderton J, Vackerott M, Rowe M, Murray PG, et al. Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin’s lymphoma. J Virol. 2011;85(18):9568–77.
12. Mundo L, Ambrosio MR, Piccalini M, Lo Bello G, Gazaneo S, Del Porro L, et al. Unveiling another missing piece in Epstein-Barr virus-driven lymphomagenesis: EBV-encoded microRNAs expression in EBV-negative Burkitt lymphoma cases. Front Microbiol. 2017;8:229.
13. Ambinder RF. Gamma herpesviruses and “Hit-and-Run” oncogenesis. Am J Pathol. 2000;156(1):1–3.
14. Birdwell CE, Queen KJ, Kilgore PC, Rollyson P, Trutschl M, Cvek U, et al. Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes. J Virol. 2014;88(19):11442–58.
15. Niller HH, Wolf H, Minaarovits J. Viral hit and run-oncogenesis: genetic and epigenetic scenarios. Cancer Lett. 2011;305(2):200–17.
16. Queen KJ, Shi M, Zhang F, Cvek U, Scott RS. Epstein-Barr virus-induced epigenetic alterations following transient infection. Int J Cancer. 2013;132(9):2076–86.
17. Hutcheson RL, Chakravorty A, Sugden B. Burkitt lymphomas evolve to escape dependencies on Epstein-Barr Virus. Front Cell Infect Microbiol. 2020;10:606412.
18. Abate F, Ambrosio MR, Mundo L, Laginestra MA, Fuligni F, Rossi M, et al. Distinct viral and mutational spectrum of endemic Burkitt lymphoma. PLoS Pathog. 2015;11(10): e1005158.
19. Vereide D, Sugden B. Proof for EBV’s sustaining role in Burkitt’s lymphoma. Semin Cancer Biol. 2009;19(6):389–93.
20. Srivinak SK, Sample JT, Sidxey JW. Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt’s lymphoma cell line. J Infect Dis. 1998;177(6):1705–9.
21. Dittmer DP, Hilscher CJ, Guille YL, Yang EV, Chen M, Glaser R. Multiple pathways for Epstein-Barr virus epithome loss from nasopharyngeal carcinoma. Int J Cancer. 2006;123(9):2105–12.
22. Trivedi P, Zhang QJ, Chen F, Minaarovits J, Ekman M, Biberfeld P, et al. Parallel existence of Epstein-Barr virus (EBV) positive and negative cells in a sporadic case of Burkitt lymphoma. Oncogene. 1995;11(3):505–10.
23. Mundo L, Del Porro L, Granai M, Siciliano MC, Mancini V, Santos R, et al. Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. Mod Pathol. 2020;33(12):2407–21.
24. Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int. 2010;60(5):337–50.
25. Nagtegaal ID, Ozde RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.
26. Netwerk CGAR. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
27. Saha A, Jha HC, Upadhyay SK, Robertson ES. Epigenetic silencing of tumor suppressor genes during in vitro Epstein-Barr virus infection. Proc Natl Acad Sci U S A. 2015;112(37):E199–207.
28. Kang GH, Lee S, Cho NJ, Gandhamidjata T, Long TI, Weisenberger DJ, et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 2008;88(2):161–70.
29. Matsusaka K, Kandara A, Nagae G, Ushiku T, Kikuchi Y, Hino R, et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 2011;71(23):7187–97.
30. Ghosh Roy S, Robertson ES, Saha A. Epigenetic impact on EBV-associated B-cell lymphomagenesis. Biomedicines. 2016;6(4):46.
31. Kong D, Ma W, Zhang D, Cui Q, Wang K, Tang J, et al. EYA1 promotes cell migration and tumor metastasis in hepatocellular carcinoma. Am J Transl Res. 2019;11(4):2328–38.
32. Wang W, Zhang Y, Liu M, Wang Y, Yang T, Li D, et al. TIMP2 is a poor prognostic factor and predicts metastatic biological behavior in gastric cancer. Sci Rep. 2018;8(1):1629.
33. Fukayama M, Kunita A, Kaneda A. Gastritis-infection-cancer sequence of Epstein-Barr virus-associated gastric cancer. Adv Exp Med Biol. 2018;1045:437–57.
34. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer. 2006;106(7):1467–79.
35. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22–9.
36. Takakuwa T, Luo WJ, Ham MF, Sakane-Ishikawa F, Wada N, Aozasa K. Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt lymphoma cell line (Raji) induces loss of BACH2 expression. Am J Pathol. 2004;164(3):967–74.
37. Lay ML, Lucas RM, Ratnamohan M, Taylor J, Ponsonby AL, Dwyer DE, et al. Measurement of Epstein-Barr virus DNA load using a novel quantification standard containing two EBV DNA targets and SYBR Green I dye. Virol J. 2010;7:252.
38. Camargo MC, Kim WH, Chiariavalli AM, Kim KM, Corvalan AH, Matsuo K, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63(2):236–43.
39. Re V, Briscotto G, Repetto O, De Zorzi M, Caggiari L, Zanussi S, et al. Overview of Epstein-Barr-virus-associated gastric cancer correlated with prognostic classification and development of therapeutic options. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21249400.
40. Sanosyan A, Fayd’herbe de Maudave A, Bolloro K, Zimmermann V, Foulongne V, Van de Perre P, et al. The impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification. PLoS ONE. 2017;12(8):e0183856.
41. Ababneh E, Saad AM, Crane GM. The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment. Histopathology. 2021;79(4):451–64.
42. Jox A, Rohen C, Belge G, Bartnitzek S, Pawlita M, Diehl V, et al. Integration of Epstein-Barr virus in Burkitt’s lymphoma cells leads to a region of enhanced chromosome instability. Ann Oncol. 1997;8(suppl 2):131–5.
43. Xu M, Zhang WL, Zhu Q, Zhang S, Yao YY, Xiang T, et al. Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus-associated malignancies. Theranostics. 2019;9(4):1115–24.
44. Chang Y, Cheng SD, Tsai CH. Chromosomal integration of Epstein-Barr virus genomes in nasopharyngeal carcinoma cells. Head Neck. 2002;24(2):143–50.
45. Xiao K, Yu Z, Li X, Tang K, Tu C, Qi P, et al. Genome-wide analysis of Epstein-Barr virus (EBV) integration and strain in C666-1 and Raji cells. J Cancer. 2016;7(2):214–24.
46. Chakravorty S, Yan B, Wang C, Wang L, Quaid JT, Lin CF, et al. Integrated pan-cancer map of EBV-associated neoplasms reveals functional host-virus interactions. Cancer Res. 2019;79(23):6010–23.
47. Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol. 2015;46(4):1421–34.
48. Tan GW, Visser L, Tan LP, van den Berg A, Diepstra A. The microenvironment in Epstein-Barr Virus-associated malignancies. Pathogens. 2018. https://doi.org/10.3390/pathogens7020040.
49. Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Selger B. Epstein-Barr virus-associated malignancies and immune escape: the role of the tumor microenvironment and tumor cell evasion strategies. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13205189.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.